Tarsus Pharmaceuticals

Historical price data

Tarsus Pharmaceuticals is a public biopharma company that achieved a significant milestone with the 2023 FDA approval of XDEMVY for Demodex blepharitis, a common eyelid disease affecting millions. The company is now executing its commercial launch while advancing a pipeline of novel candidates, including TP-03 for Meibomian Gland Disease and TP-04 for rosacea, based on its targeted therapeutic approach. Tarsus's strategy is to identify and develop treatments for prevalent, underserved conditions, aiming to establish a leading position in medical dermatology and ophthalmology.

Targeted therapeutic strategy focused on developing and repurposing novel small molecules against validated biological pathways in high-prevalence, underserved diseases, particularly in ophthalmology and dermatology.

11 drugs in pipeline, 2 in Phase 3

Total raised: $126M

XDEMVY faces competition from off-label treatments but is the only FDA-approved therapy for Demodex blepharitis. In pipeline indications like MGD and rosacea, Tarsus will compete with established drugs, but its targeted mechanism against Demodex mites offers a differentiated approach for a subset of patients.